STILL’S DISEASE TREATMENT MARKET ANALYSIS

Regional Analysis

 Global Still’s Disease Treatment Market - Regional Analysis

Among region, North America is estimated to hold a dominant position in the global Still’s disease treatment market over the forecast period, owing to increasing clinical trials of the drugs for the treatment of Still’s diseases. For instance, on May 5, 2021, Avalo Therapeutics, a U.S.-based biotechnology company, announced that it has dosed its first patient in a Phase 1b open-label dose-escalation clinical trial of CERC-007 in patients with Adult Onset Still’s Disease (AOSD). CERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb). IL-18 has been demonstrated to have a key role as a marker of disease activity and its concentration correlates with disease severity in AOSD patients. Proof-of-concept of anti-IL-18 therapy has been demonstrated, establishing the clinical utility of this mechanism for patients with AOSD.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa